Home
Drugs
Pembrolizumab

Pembrolizumab

Drug

Also known as: Keytruda Qlex, KEYTRUDA QLEX, KEYTRUDA QLEX™

Drug Profile

Keytruda is the brand name for pembrolizumab, a human PD-1 blocking antibody used across a broad range of cancers. It is approved in multiple tumor types and biomarker-defined settings, including melanoma, lung, head and neck, gastrointestinal, gynecologic, and urothelial cancers. The FDA first approved Keytruda in 2014.

Drug Class: PD-1 (programmed death receptor-1) blocking antibody
Approval Status: FDA approved; first approved September 4, 2014.
Mechanism of Action: Blocks programmed death receptor-1 (PD-1) signaling as an immune checkpoint inhibitor.

Brand Names

Keytruda

Indications

Melanoma
\Non-small cell lung cancer\
\Head and neck squamous cell cancer\
\Hodgkin lymphoma\
\Urothelial cancer\
\Gastric cancer\
\Esophageal cancer\
\Cervical cancer\
\Hepatocellular carcinoma\
\Renal cell carcinoma\
\Endometrial carcinoma\
\Biliary tract cancer\

Related News

FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth

Jun 23, 2026

The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.

New Research Advances Cancer Immunotherapy Through Clinical Data, Resistance Mechanisms, and Microbiome Insights

Jun 21, 2026

New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.

Multiple Studies Highlight Differing Immunotherapy Outcomes in Advanced NSCLC

Jun 14, 2026

Multiple recent studies evaluate different immunotherapy approaches for advanced NSCLC, including long-term benefits for nivolumab plus ipilimumab with chemotherapy in PD-L1-negative tumors, limited advantages from PD-(L)1 rechallenge strategies, and early positive signals from combining TIGIT and PD-1 inhibitors in PD-L1-high patients.

AI and mRNA Cancer Vaccine Shows 49% Reduction in Melanoma Relapse at ASCO 2026

Jun 11, 2026

Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.

Oncology Drug Market Sees Strong Growth Amid Patent Cliffs and Novel Modality Shifts

Jun 05, 2026

Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.

RAMPART Trial: Durvalumab Monotherapy Lacks DFS Benefit in Resected RCC; Combination Shows Benefit in High-Risk Patients

Jun 04, 2026

The phase 3 RAMPART trial updated results show adjuvant durvalumab monotherapy did not significantly improve disease-free survival in resected renal cell carcinoma, while the durvalumab plus tremelimumab combination showed benefit in high-risk patients. Real-world treatment decisions are also shaped by patient-specific factors.

Pfizer Secures FDA Approvals for Two Cancer Drugs; Oncolytic Virus Pipeline Expands

Jun 01, 2026

The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.

BioNTech Faces Mixed Analyst Views, FDA Fast-Track Designation, and Leadership Transition

May 26, 2026

BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.

European Biotechs Advance Next-Generation Immunotherapy Targets Beyond PD-1/PD-L1

May 01, 2026

European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.

Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer and Refines Chemotherapy Decisions in Germ Cell Tumors

Apr 30, 2026

Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07610941	Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies	RECRUITING	PHASE1
NCT07610525	Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial	NOT_YET_RECRUITING	PHASE2
NCT07594015	Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy	RECRUITING	PHASE2
NCT07591597	A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07578649	Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer	NOT_YET_RECRUITING	PHASE3
NCT07572123	Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma	NOT_YET_RECRUITING	PHASE2/PHASE3
NCT07566156	Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )	RECRUITING	PHASE3
NCT07565285	The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma	NOT_YET_RECRUITING	PHASE2
NCT07552558	Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07541170	A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)	NOT_YET_RECRUITING	PHASE3